Br[CH2:2][C:3]([O:5][C@H:6]([C:17]1[CH:22]=[CH:21][C:20]([O:23][CH:24]([F:26])[F:25])=[C:19]([O:27][CH2:28][CH:29]2[CH2:31][CH2:30]2)[CH:18]=1)[CH2:7][C:8]1[C:13]([Cl:14])=[CH:12][N+:11]([O-:15])=[CH:10][C:9]=1[Cl:16])=[O:4].BrCC(O[C@H](C1C=CC(OC(F)F)=C(OCC2CC2)C=1)CC1C(Cl)=CN=CC=1Cl)=O.C([O-])([O-])=O.[K+].[K+].[CH3:68][S:69]([NH:72][C:73]1[CH:82]=[CH:81][CH:80]=[CH:79][C:74]=1[C:75]([O:77][CH3:78])=[O:76])(=[O:71])=[O:70]>CN(C=O)C.O>[Cl:16][C:9]1[CH:10]=[N+:11]([O-:15])[CH:12]=[C:13]([Cl:14])[C:8]=1[CH2:7][C@@H:6]([C:17]1[CH:22]=[CH:21][C:20]([O:23][CH:24]([F:26])[F:25])=[C:19]([O:27][CH2:28][CH:29]2[CH2:31][CH2:30]2)[CH:18]=1)[O:5][C:3](=[O:4])[CH2:2][N:72]([C:73]1[CH:82]=[CH:81][CH:80]=[CH:79][C:74]=1[C:75]([O:77][CH3:78])=[O:76])[S:69]([CH3:68])(=[O:71])=[O:70]The mixture obtained in step 2, containing (S)-4-(2-(2-bromoacetoxy)-2-(3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl)ethyl)-3,5-dichloropyridine (100 mg) was dissolved in DMF (2 ml), and K2CO3 (30 mg, 0.22 mmol) and methyl 2-(methylsulfonamido)benzoate (82 mg, 0.36 mmol) were added. The mixture was stirred at RT for 5 hours. The reaction was diluted with water, and the product was extracted with EtOAc. The organic layer was washed with water, dried over Na2SO4 and evaporated under vacuum. The crude product was purified by preparative reverse-phase HPLC to give 105 mg of the desired product (Yield: 85%, MS/ESI+ 689.5 [MH]+).